ALK-Abello A/S (AKBLF)
37.92
0.00 (0.00%)
USD |
OTCM |
Aug 28, 16:00
ALK-Abello Net Income (Quarterly) : 52.74M for June 30, 2026
Net Income (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 52.74M |
| March 31, 2026 | 68.43M |
| December 31, 2025 | 41.46M |
| September 30, 2025 | 49.17M |
| June 30, 2025 | 39.95M |
| March 31, 2025 | 49.94M |
| December 31, 2024 | 24.31M |
| September 30, 2024 | 31.22M |
| June 30, 2024 | 29.01M |
| March 31, 2024 | 33.77M |
| December 31, 2023 | 20.19M |
| September 30, 2023 | 17.08M |
| June 30, 2023 | 9.642M |
| March 31, 2023 | 23.50M |
| December 31, 2022 | 10.70M |
| September 30, 2022 | 7.037M |
| June 30, 2022 | 6.008M |
| March 31, 2022 | 24.58M |
| December 31, 2021 | 11.68M |
| September 30, 2021 | 5.865M |
| June 30, 2021 | -3.405M |
| March 31, 2021 | 20.57M |
| December 31, 2020 | -4.965M |
| September 30, 2020 | -3.140M |
| June 30, 2020 | -1.477M |
| Date | Value |
|---|---|
| March 31, 2020 | 12.68M |
| December 31, 2019 | -4.298M |
| September 30, 2019 | -2.086M |
| June 30, 2019 | -10.23M |
| March 31, 2019 | 6.846M |
| December 31, 2018 | -22.33M |
| September 30, 2018 | -4.836M |
| June 30, 2018 | -2.718M |
| March 31, 2018 | 3.961M |
| December 31, 2017 | -25.15M |
| September 30, 2017 | 0.00 |
| June 30, 2017 | -0.1481M |
| March 31, 2017 | 0.2867M |
| December 31, 2016 | 5.215M |
| September 30, 2016 | 5.848M |
| June 30, 2016 | 10.93M |
| March 31, 2016 | 18.18M |
| December 31, 2015 | 20.39M |
| September 30, 2015 | 9.235M |
| June 30, 2015 | 8.005M |
| March 31, 2015 | 13.43M |
| December 31, 2014 | 2.686M |
| September 30, 2014 | 4.622M |
| June 30, 2014 | 5.696M |
| March 31, 2014 | 19.83M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| Novo Nordisk A/S | 3.265B |
| H. Lundbeck A/S | 178.61M |
| AstraZeneca PLC | 3.076B |
| ANI Pharmaceuticals, Inc. | 23.00M |
| Corcept Therapeutics, Inc. | 42.14M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 279.27M |
| Total Expenses (Quarterly) | 226.53M |
| EPS Diluted (Quarterly) | 0.2377 |
| Enterprise Value | 8.212B |
| Gross Profit Margin (Quarterly) | 66.57% |
| Profit Margin (Quarterly) | 18.89% |
| Earnings Yield | 2.52% |
| Operating Earnings Yield | 3.39% |
| Normalized Earnings Yield | 2.520 |